On August 25, Yabao Pharmaceutical(600351) issued an announcement that its controlling subsidiary Suzhou Yabao Pharmaceutical Research and Development Co., Ltd. recently received the "Drug Clinical Trial Approval Notice" for the new indication of SY-005 injection approved and issued by the National Medical Products Administration.
The approval notice allows the clinical trial of SY-005 injection for the treatment of neurological deficits after glioma surgery. The application is for the treatment of neurological deficits after glioma surgery, and the drug registration classification is a therapeutic biological product.Category 1.
As of the date of this announcement, the company has invested approximately RMB 127 million in R&D for the SY-005 project. SY-005 is an innovative recombinant protein .In November 2018, the company received approval for a clinical trial for the treatment of sepsis, and this indication is currently in Phase II clinical trials. Glioma is the most common primary intracranial malignant tumor, and postoperative neurological deficits are a common complication that impacts patients' quality of life.
By mid-2025, Yabao Pharmaceutical achieved revenue of 1.139 billion yuan and net profit attributable to shareholders of the parent company of 174 million yuan.
https://finance.eastmoney.com/a/202508253493526121.html